DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma
July 17th 2023The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.
Read More
Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC
July 14th 2023Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.
Read More
Despite Diagnostic Challenges, ADCs Are Poised to Expand Treatment Options in Lung Cancer
July 13th 2023As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.
Read More
Trastuzumab Deruxtecan Confers Response in HER2+ Gastric/GEJ Cancer in Updated Analysis
July 10th 2023Treatment with trastuzumab deruxtecan resulted in clinically meaningful efficacy in patients with HER2-positive gastric or gastroesophageal junction cancer following disease progression on or after a trastuzumab-containing regimen.
Read More
Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC
July 9th 2023The addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared with standard of care alone for patients with metastatic castration-resistant prostate cancer.
Read More
Jaktinib Displays Significant Benefit Vs Hydroxyurea in Intermediate-2/High-Risk Myelofibrosis
June 10th 2023Patients with intermediate-2 or high-risk myelofibrosis who received the novel JAK/ACVR1 inhibitor jaktinib experienced a statistically significant improvement in the proportion of patients with a spleen-volume reduction of at least 35% from baseline at week 24 vs those who were treated with hydroxyurea.
Read More
A2B530 Harnesses Unique Mechanism of Action to Integrate CAR T in Solid Tumors
June 8th 2023Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in the EVEREST trial.
Read More
Trastuzumab Deruxtecan Elicits Responses in Difficult-To-Treat HER2+ Solid Tumors
June 5th 2023Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.
Read More
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
June 2nd 2023Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.
Read More
Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer
June 2nd 2023Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.
Read More
Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin Lymphoma
May 31st 2023Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.
Read More
Latinx Patients Highlight Barriers to Tumor Genomic Profiling for Cancer
May 29th 2023Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.
Read More
SPEECH Conference Highlights Multiplicity of Ongoing Efforts in Cancer Care Equity
May 23rd 2023Young investigators, fellows, and medical students recently gathered at the Temple University Lewis Katz School of Medicine in Philadelphia, Pennsylvania, to network and share exciting research aimed at addressing disparities in the dissemination of cancer care at the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health Conference and Retreat.
Read More
Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC
May 17th 2023Triplet therapy consisting of encorafenib, cetuximab, and binimetinib demonstrated activity and manageable safety as first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More
EVEREST-1 Trial Seeks to Bring HLA-A*02-directed CAR T to Patients With Solid Tumors
May 16th 2023The upcoming phase 1/2 EVEREST-1 trial, where the novel CAR T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.
Read More
mRNA Vaccine Autogene Cevumeran Plus Atezolizumab and Chemotherapy Displays Early Efficacy in PDAC
May 12th 2023Adjuvant treatment with the individualized RNA neoantigen vaccine autogene cevumeran in combination with atezolizumab and chemotherapy induced notable T-cell activity that could be correlated with delayed recurrence in patients with pancreatic ductal adenocarcinoma.
Read More